New Trustees begin their terms of service on Board
The new Term, Alumni and Commonwealth Trustees attended their first Board meeting on Feb. 17.
Term Trustees
The three new Term Trustees, who were appointed on Oct. 31, 1998 and will serve until Oct. 30, 2003, are:
Dr. Mitchell J. Blutt (C'78, M 82, W'87), Executive Partner at Chase Capital Partners in New York and an adjunct professor at New York Hospital-Cornell Medical Center;
Mitchell I. Quain (EE'73), Executive Vice President of ING Baring Furman Selz and former managing director of Wertheim Schroder & Company, Inc.; and
David M. Silfen (C'66), a limited partner of Goldman Sachs & Company, a New York-based investment firm.
Alumni Trustees
The two new Alumni Trustees, who were named on Jan. 1, 1999 and will serve until Dec. 31, 2003, are:
Alan G. Hassenfeld (C'70), Chairman and CEO of Hasbro, Inc. and a past member of the Brown University Board of Trustees; and
David P. Montgomery (C'68, WG'70), President and CEO of the Philadelphia Phillies Baseball Club and the chairman of the Schuylkill Valley Nature Center Capital Campaign.
The new Commonwealth Trustee, Robert A. Gleason Jr. (W'61) ("Appointments," Current, Jan. 28), will serve a term concurrent with that of Pennsylvania Senate President Pro Tempore Robert Jubelirer.
When the Schuylkill swallowed the city: Lessons from Hurricane Ida’s historic flood
New Penn research shows that Hurricane Ida wasn’t a once-in-a-century anomaly but a preview of how climate change, urbanization, and aging infrastructure are rewriting flood risk.
The Fed explained: What it does and why it matters
Former Philadelphia Fed President Patrick Harker and financial historian Peter Conti-Brown, both Wharton professors, unpack the central bank’s origins, its unusual structure, and the quiet ways it shapes the economy
How population changes are impacting primary education worldwide
Research from Penn sociologist Emily Hannum and colleagues reveals regional trends in whether school-age populations are increasing, plateauing, or decreasing—and shows how different countries are responding.
A bioengineered bean gum from the lab of Penn Dental’s Henry Daniell is found to reduce the levels of three microbes associated with head and neck squamous cell cancer to almost zero, without affecting the beneficial bacteria normally found in the mouth.
Fighting oral cancer with bioengineered chewing gum
Research led by Penn Dental’s Henry Daniell shows that antiviral and antibacterial chewing gums reduce the levels of three microbes linked to worse outcomes in oral cancers, paving the way for more effective and affordable therapies.
